Italy has quietly enacted what advocates are calling a revolution in workplace rights for women with endometriosis, obliging employers to provide “reasonable accommodations” for a condition that affects roughly one in ten women of reproductive age. The move, viewed from Rome as a belated recognition that chronic illness can become a social status that marginalises sufferers, draws on the principle that labour is not merely a means of subsistence but a “laborious conquest of autonomy and the construction of community bonds.” By treating endometriosis as a condition warranting adjustments akin to disability provisions, Italian policymakers have set a precedent that analysts in London say could ripple across European labour law.

Yet the Italian breakthrough lands amid a starkly different crisis in Scandinavia. Sweden is grappling with an acute shortage of oestrogen-based hormone therapy for menopause, forcing thousands of women into what local media have dubbed “menopause tourism” — cross-border journeys to obtain preparations that are listed as backordered at virtually every pharmacy in the country. Professor Helena Kopp Kallner, a senior obstetrician-gynaecologist, described the situation as scandalous and a magnification of already unequal care in women’s health. Artist and activist Anna Sahlin called it a systemic betrayal, noting that the shortage has become a symbol of how female health is prioritised. The supply crunch, driven by surging demand that manufacturers failed to anticipate, has left women interrupting treatments and spending enormous energy hunting for alternatives.

Access to menopause therapies is constrained on multiple fronts. In Spain and beyond, millions of women are excluded from hormone replacement not by logistics but by medical history: a diagnosis of oestrogen-sensitive breast cancer, like the one received by 46-year-old Cybele Maylone, makes such treatment too dangerous. Even as influencers and peers tout the transformative effects of HRT — vanishing hot flushes, lifted brain fog, restored sleep — a vast population is left watching from the sidelines. Meanwhile, endometriosis, an incurable disease that shapes fertility, life planning and social participation, continues to illustrate the political dimension of women’s health. In Germany, women like Miriam Birrer endure decades of pain and multiple surgeries with no guarantee of relief. In Colombia, a law to improve diagnosis and treatment was approved, but the patient association ASOCOEN has publicly denounced the health ministry’s lack of clarity on implementation, leaving the legislation in limbo.

Viewed from São Paulo, a contrasting narrative of medical progress emerges: Edgard de Luna, diagnosed with pancreatic cancer at 42 and given a five per cent chance of survival, is now eight years free of detectable disease. Such oncological breakthroughs underscore what is possible when research, funding and clinical urgency align. Yet the global picture reveals a persistent disparity. Chronic, non-fatal but life-altering conditions that disproportionately affect women — endometriosis, menopausal symptoms — remain under-researched, underfunded and subject to supply-chain fragilities. Italy’s accommodation law may offer a template for workplace inclusion, but forward-looking analysts argue that closing the gap will require coordinated action on drug manufacturing resilience, dedicated research programmes, and the political will to turn paper laws into lived protections from Bogotá to Berlin.